Ignite Creation Date:
2024-05-05 @ 5:07 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00396279
Status:
COMPLETED
Last Update Posted:
2022-11-08
First Post:
2006-11-02
Brief Title:
Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
An Open-Label Multi-Center Phase 2 Safety and Efficacy Study of Denosumab AMG 162 in Subjects With Recurrent or Unresectable Giant Cell Tumor GCT of Bone
Status:
COMPLETED
Status Verified Date:
2022-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine how safe and effective denosumab is in treating patients with giant cell tumor of bone
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None